L01CE02 • irinotecan • Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Topoisomerase 1 (TOP1) inhibitors
Irinotecan is a chemotherapy medication used to treat metastatic colorectal cancer, usually in combination with other drugs. It works by inhibiting the enzyme topoisomerase I, which is essential for DNA replication in cancer cells, thereby causing their death.
The medication is administered intravenously under the supervision of an oncologist, and the dosage is adjusted based on body weight and the patient's overall condition.
Side effects may include severe diarrhea, nausea, vomiting, decreased blood cell counts, or hair loss. In rare cases, severe allergic reactions or liver toxicity may occur.
Patients should be closely monitored during treatment and inform their doctor about any other medications they are taking. Pregnant or breastfeeding women should not use this medication.
Substance: irinotecan
Date of last drug list: 01-06-2025
Commercial code: W65011003
Concentration: 20mg / ml
Pharmaceutical form: perfusive solution concentrate
Quantity: 1
Product type: generic
Price: 606.83 RON
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: FRESENIUS KABI ONCOLOGY PLC - MAREA BRITANIE
Holder: FRESENIUS KABI ROMANIA S.R.L. - ROMANIA
Number: 8422/2015/03
Shelf life: 2 years-dupa ambalarea dupa comercilaizare;after the first opening of the bottle-it is used immediately